SD Union Tribune announces Batu’s $1M seed funding

Batu Biologics has raised $1 million to develop its lung cancer immune therapy, the two-year-old San Diego company said Wednesday.

The therapy, ValloVax, is intended to stimulate an immune response against new blood vessels in the lung that tumors use to grow. In preclinical testing, ValloVax inhibited angiogenesis in melanoma, breast and lung cancer mouse models.

Read the full article at utsandiego.com

0